Press release

2 February 2006

Shogoo and BioSphings announce a world-wide exclusive license agreement for SPK-0601

Shogoo Pharmaceuticals K.K. (“Shogoo”), a Tokyo based specialty pharmaceutical company, announced today that it has signed an agreement with BioSphings AG (“BioSphings”), a Frankfurt based biopharmaceutical company, to obtain BioSphings’ intellectual property rights to develop and commercialize SPK-0601, a small molecule compound for the treatment of diseases caused by viral infection. Under the terms of the agreement, Shogoo obtains such intellectual property rights on a world-wide and exclusive basis. BioSphings will support Shogoo’s global development of SPK-0601.
Financial terms were not disclosed, however, BioSphings will receive upfront and milestone payments based on the development progress and royalty on sales.

Mr. Yoshihiro Toyohara, the president and Chief Executive Officer of Shogoo said, “We are very excited with this global opportunity as SPK-0601 is potentially applicable for the treatment of diseases induced by widely prevailing viruses such as HSV, VZV and HPV. Shogoo will closely collaborate with BioSphings to maximize the value of SPK-0601.”

“We are pleased that Shogoo has decided to explore the exciting opportunity of SPK-0601", said Dr. Marc Roesel, Chief Operating Officer of BioSphings. "This agreement highlights the value of BioSphings' technology. We are looking forward to working with Shogoo and entering this promising antiviral drug candidate into clinical trials".

About SPK-0601
SPK-0601 is a small molecule compound which acts on viral gene expression in host cells infected by virus. As SPK-0601 targets not viral proteins but host cell’s proteins, it is expected not to induce mutant virus which potentially show drug-resistance to SPK-0601. In addition, SPK-0601 may be used concomitantly with other anti-viral drugs which inhibit the activities of viral proteins such as HSV’s thymidine kinase.

About Shogoo Pharmaceuticals, K.K.
Shogoo is a specialty pharmaceutical company based in Tokyo, Japan, focusing on in-licensing, developing and commercializing product candidtes from overseas. Shogoo targets the therapeutic areas with high unmet medical needs. For more information, please visit

About BioSphings AG
BioSphings, a biopharmaceutical company based in Frankfurt, Germany, focuses on the development of novel therapeutic approaches for the treatment of cancer, autoimmune diseases and viral infections.
The privately held company owns a portfolio of protected drug candidates which target pathways of the lipid metabolism. BioSphings was founded as a spin-off of the DKFZ (German Cancer Research Center), Heidelberg, and was supported during its early stages by Cancer Research Technology Ltd., London.

Contact for inquiries or additional information:
Shogoo Pharmaceuticals K.K.
Ko Hasegawa, Ph.D.
Licensing Director

This news release contains certain forward-looking statements that involve risk and uncertainties. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the risk that products that appeared promising in early research and clinical trials do not demonstrate safety and efficacy in larger-scale clinical trials and the risk that the company will not obtain approval to market the products.


© BioSphings AG 2006